Сравнение на методи

	Кръстосан контролен групов експериментален дизайн	Кръстосано рандомизирано контролирано проучване
Област	Планиране на експеримента	Планиране на експеримента
Семейство	Process / pipeline	Process / pipeline
Година на възникване	Mid-20th century; systematic treatment from 1980s onward	1960s (Grizzle 1965 for statistical foundations); widely used in clinical research since the 1970s
Създател	Established in clinical pharmacology and agricultural research; formalized by B. Jones & M. G. Kenward	Early formalized by statisticians including Bradford Hill and colleagues in clinical trials; theoretical framework developed by Grizzle (1965) and later Senn (2002)
Тип	Experimental design	Experimental within-subject design
Основополагащ източник	Jones, B., & Kenward, M. G. (2003). Design and Analysis of Cross-Over Trials (2nd ed.). Chapman and Hall/CRC. ISBN: 978-1584883500	Senn, S. (2002). Cross-over Trials in Clinical Research (2nd ed.). Wiley. ISBN: 978-0471496533
Други названия	crossover controlled trial, within-subject crossover with control, AB/BA crossover controlled design, repeated-measures crossover with control arm	crossover RCT, crossover trial, within-subject RCT, AB/BA crossover design
Свързани	6	5
Резюме	A crossover control group experimental design is an experimental approach in which participants are randomly assigned to sequences of conditions that include both a treatment and a control (no-treatment or placebo) period, with each participant experiencing both the experimental and control conditions in succession. By using each participant as their own control across periods, this design sharply reduces between-subject variability and typically requires fewer participants than parallel group trials to achieve equivalent statistical power.	A crossover randomized controlled trial (crossover RCT) is an experimental design in which each participant receives all study interventions in a randomized sequence, separated by a washout period. Because every participant serves as their own control, within-subject variability is eliminated from the treatment comparison, yielding greater statistical power per participant than a parallel-group RCT of equal size.